1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249.
2. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020; 21(7): e342-e349.
3. Nelson BE, Hong A, Jana B. Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. Front Oncol. 2021;11:705294.
4. Al-Baradie ༲, Yamada K, St Hilaire C, et al. Duane radial ray syndrome ( Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family. Am J Hum Genet. 2002;71( 5):1195-1199.
5. Zhang X, Yuan X, Zhu W, et al. SALL4: An emerging cancer biomarker an target. Cancer lett. 2015; 357(1):55-62.
6. Oikawa T, Kamiya A, Kakinuma S, et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology. 2009;136(3):1000–1011.
7. Miettinen M, Wang ZF, McCue P A, et al. SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases. Am J Surg Pathol. 2014;38(3): 410–420.
8. Oikawa T, Kamiya A, Zeniya M, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013;57(4):1469–1483.
9. Cheng J, Deng R, Wu C, et al. Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression. Int J Clin Exp Pathol. 2015;8(9):10092–10101.
10. Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol. 2011;38(4): 933–939.
11. Liu L, Zhang J, Yang X, et al. SALL4 as an epithelial-mesenchymal transition and drug resistance inducer through the regulation of c-Myc in endometrial cancer. PLoS One. 2015;10(9):e0138515.
12. Yanagihara N, Kobayashi D, Kuribayashi K, et al. Significance of SALL4 as a drug resistant factor in lung cancer. Int J Oncol. 2015;46(4):1527–1534.
13. He J, Zhang W, Zhou Q, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol. 2013;45(9):1962–1973.
14. Diener J, Baggiolini A, Pernebrink M, et al. Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. Nat Commun. 2021;12(1):5056.
15. Li J, Zhang Y, Tao X, et al. Knockdown of SALL4 inhibits the proliferation, migration, and invasion of human lung cancer cells in vivo and in vitro. Ann Transl Med. 2020;8(24):1678.
16. Sun J, Tang Q, Gao Y, et al. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling. J Exp Clin Canc Res. 2020;39(1):104.
17. Chen T, Tsang JYS, Su XC, et al. SALL4 promotes tumor progression in breast cancer by targeting EMT. Mol Carcinogen. 2020;59(10):1209-1226.
18. Yang Y, Wang XH, Liu YQ, et al. Up-Regulation of SALL4 is associated with survival and progression via putative WNT pathway in gastric cancer. Front Cell Dev Biol. 2019;9:600344.
19. Gloushankova N A, Zhitnyak I Y, Rubtsova S N. Role of Epithelial- Mesenchymal Transition in Tumor Progression. Biochemistry. 2018;83(12): 1469-1476.
20. Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395-412.
21. Thiery J P, Acloque H, Huang R Y, et al. Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 2009; 139(5):871-890.
22. Singh R, Ansari J A, Maurya N, et al. Epithelial-to-mesenchymal transition and its correlation with clinicopathological features in patients with urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2017;15(2): e187-e197.
23. Baumgart E, Cohen M S, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors༎Clin Cancer Res. 2007;13(6):1685-1694.
24. Ji H, Lu HW, Li YM, et al. Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through grouth differentiation factor15. Mol Med Rep. 2015;12(3):3841-3848.
25. Zhang X, Zhang P, Shao M, et al. SALL4 activates TGF-β/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis. Cancer Manag Res. 2018;10:4459-4470.
26. Itou J, Matsumoto Y, Yoshikawa K, et al. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer. FEBS Lett. 2013;587:3115–3121.
27. Zhang L, Wu B, Zha Z, et al. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):716.
28. Li A, Jiao Y, Yong K J, et al. SALL4 is a new target in endometrial cancer. Oncogene. 2015;34(1):63-72.
29. Yin F, Han X, Yao S K, et al. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma. World J Gastroenterol. 2016;22(9): 2837-2843.
30. Jiang G, Liu C T. Knockdown of SALL4 overcomes cisplatin-resistance through AKT/mTOR signaling in lung cancer cells. Int J Clin Exp Pathol. 2018;11(2):634-641.
31. Zhang L, Xu Z, Xu X, et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 2014;33(48):5491–5500.
32. Mathieu R, Lucca I, Rouprêt M, et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8): 471-479.
33. Kobayashi D, Kuribayashi K, Tanaka M, et al. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011;26(4): 965-970.
34. He J, Zhou M, Chen X, et al. Inhibition of SALL4 reduces tumorigenicity involving epithelial-Mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35(1):98.
35. Forghanifard M M, Moghbeli M, Raeisossadati R, et al. Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci. 2013;20(1):6.
36. Shome R, Ghosh S S. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation. Cell Oncol(Dordr). 2021;44(2):405-422.
37. Li S, Liu F, Xu L. Wnt/β-Catenin Signaling Axis Is Required for TFEB-Mediated Gastric Cancer Metastasis and Epithelial-Mesenchymal Transition. Mol Cancer Res. 2020;18(11):1650-1659 .
38. Ma Y, Cui W, Yang J, et al. SALL4, a noval oncogene, is constitutively expressed in human acute myeloid leukemia(AML) and induces AML in transgenic mice. Blood. 2006;108(8):2726-2735.
39. Chen M, Li L, Zheng P S. SALL4 promotes the tumorigenicity of cervical cancer cells through activation of the Wnt/β-catenin pathway via CTNNB1. Cancer Sci. 2019;110(9):2794-2805.
40. Ahmad I, Morton J P, Singh L B, et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene. 2011;30(2):178-189.
41. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res. 2006;12(2):383-391.